Imre Berger, Cristiane Schaffitzel, Mick Bailey, David Matthews and Imophoron Ltd.
The work: Testing synthetic COVID-19 VLP vaccine candidates using the thermostable ADDomer© vaccine. The bioengineered ADDomer candidate is a virus-like particle vaccine, created by generating generic VLP and engineering antigens onto the surface. The principle vaccine was tested on the arbovirus, chikungunya, in 2019 and now the ADDomer vaccine candidate is being applied to COVID-19. The G1 B antigen is currently being tested in pre-clinical models, with G2 B and T antigen tests to follow.
Funding: EU Advanced Grant, Wellcome Trust, BBSRC